Alternatives to Sotalol If You Can't Fill Your Prescription

Sotalol is a mainstay antiarrhythmic medication for both atrial fibrillation and ventricular arrhythmias. But when the oral solution is unavailable or the tablet is temporarily out of stock, many patients are left wondering: what now? The good news is that several alternative antiarrhythmic medications exist — and the right one for you depends on your specific cardiac diagnosis, heart structure, kidney function, and other health factors. Always work with your cardiologist before switching medications.

Important safety note: Never stop Sotalol abruptly. As a beta-blocker, sudden discontinuation can cause dangerous rebound tachycardia and arrhythmias. If you're running low, contact your cardiologist before missing doses.

Understanding Why Alternatives Aren't Interchangeable

Antiarrhythmic drugs are classified by their mechanism of action into four Vaughan-Williams classes. Sotalol is unique because it has both Class II (beta-blocking) and Class III (potassium channel blocking) properties. No other single drug replicates this exact dual mechanism. Alternatives work differently and carry their own sets of benefits and risks. Your cardiologist will choose based on the type of arrhythmia you have, whether you have structural heart disease, your kidney function, and other medications you take.

Alternative 1: Amiodarone (Pacerone, Cordarone)

Amiodarone is the most commonly prescribed antiarrhythmic in the U.S. and is considered more effective than Sotalol for keeping patients in normal sinus rhythm — with studies showing maintenance rates of 62–69% at one year compared to approximately 37% for Sotalol. It is a Class III antiarrhythmic with additional properties from all four Vaughan-Williams classes.

Amiodarone can be used in patients with structural heart disease, including those with heart failure — where Sotalol is not appropriate. It carries a relatively low risk of torsade de pointes compared to other Class III agents.

Key considerations: Amiodarone requires regular monitoring for thyroid, liver, and pulmonary toxicity — side effects that can develop months or years into treatment. It has a very long half-life (up to 100 days) and numerous drug interactions. Despite this, it is often preferred for patients with reduced ejection fraction or structural heart disease.

Alternative 2: Dronedarone (Multaq)

Dronedarone is a structural derivative of amiodarone developed to retain antiarrhythmic efficacy while reducing the toxic side effects. It is approved for maintenance of sinus rhythm in atrial fibrillation and flutter. Unlike Sotalol, dronedarone can typically be started as an outpatient, without the 3-day hospital monitoring required for Sotalol initiation.

Studies comparing dronedarone to Sotalol in AFib patients found similar effectiveness for cardiovascular hospitalization and death, with a lower rate of ventricular proarrhythmia with dronedarone.

Key considerations: Dronedarone is contraindicated in patients with moderate to severe heart failure or permanent AFib. It cannot be used for ventricular arrhythmias. Its convenience advantage over Sotalol (outpatient initiation) makes it a popular first choice in appropriate patients.

Alternative 3: Dofetilide (Tikosyn)

Dofetilide is a pure Class III potassium channel blocker approved for converting and maintaining sinus rhythm in atrial fibrillation. Like Sotalol, it must be initiated in the hospital with continuous ECG monitoring. It carries a risk of torsade de pointes and requires careful renal dose adjustment.

Key considerations: Dofetilide is contraindicated with many common medications due to pharmacokinetic interactions. It is not available in Europe or Australia, but is widely used in the U.S. It requires a specific training program (REMS) for prescribers. Combined with Sotalol, dofetilide is absolutely contraindicated.

Alternative 4: Flecainide (Tambocor)

Flecainide is a Class IC antiarrhythmic that works by blocking sodium channels. It is approved for paroxysmal AFib and SVT in patients without structural heart disease. Unlike Sotalol, it can be prescribed outpatient and can be used as a "pill-in-the-pocket" for patients with infrequent AFib episodes.

Key considerations: Flecainide must be avoided in patients with significant structural heart disease, coronary artery disease, or reduced ejection fraction because it can cause sustained ventricular tachycardia in those settings. In structurally normal hearts, it is generally well-tolerated with a low risk of torsade de pointes.

Alternative 5: Propafenone (Rythmol SR)

Propafenone is another Class IC antiarrhythmic with additional mild beta-blocking properties, making it somewhat similar to Sotalol in profile — though the mechanism of action differs significantly. It is available in an extended-release formulation (Rythmol SR) that allows for twice-daily dosing.

Key considerations: Like flecainide, propafenone is contraindicated in structural heart disease. It is metabolized by the liver (unlike Sotalol, which is renally excreted), so kidney impairment is less of a concern. It can cause a metallic taste and GI discomfort.

How to Talk to Your Cardiologist About Switching

When calling your cardiologist about a Sotalol shortage, be prepared to provide:

Your current Sotalol dose and how long you've been taking it

Your specific heart condition (e.g., paroxysmal AFib, persistent AFib, ventricular tachycardia)

Any other heart conditions (heart failure, coronary artery disease, LV dysfunction)

Your kidney function (eGFR or creatinine clearance) — important since Sotalol is renally excreted

All current medications, including supplements

Before concluding that an alternative is needed, exhaust all options to locate Sotalol. See our guide: How to Find Sotalol In Stock Near You.

If you haven't already, try medfinder — we contact pharmacies near you to check which ones can fill your Sotalol prescription, saving you hours of calling around.